reason report
new product cycl drive continu growth acceler
bottom line share trade today despit deliv
believ solid quarter compani
demonstr acceler oper sale --
 intern come top end
guidanc rang y/i ad full point sequenti
sale growth continu oper leverag margin
improv bp vs vs
ep guidanc rais repres penni increas
impli back half guidanc admittedli print bit
complic bax recent slew consist beat rais
quarter given unexpect weak nutrit medic
deliveri due seemingli transit issu bring suppli
on-board mexico customers/distribut partner continu
ramp post-hurrican maria cap potenti sale upsid
otherwis would seen view weak share
buy opportun reiter top large-cap pick
still see upsid potenti reiter top-lin guidanc
oper driven new product cycl across busi
includ continu roll-out amia periton dialysi cycler
japan launch kaguya pd periton dialysi renal
recent approv infus system spectrum iq
canada evo iq europ europ launch tisseel
prima advanc surgeri regardless continu believ
drive sustain consist out-performance forese
futur potenti upsid recent updat long-term
sale guidanc compound-annual-growth-rate time-frame
believ still underappreci street
signific financi flexibl balanc sheet like
increasingli activ share repurchas
reiter op pt next month believ share
trade rang dcf valuat deriv
base case upsid scenario supplement
price target arriv via ev/fcf ev/ ebitda analys
now-high estim price-to-earnings perspect valuat
appli multipl now-high ep estim
vs previous assum multipl expans
current level pe ep support
consist beat rais quarter estim continu
ep estim move higher ep
estim move previous
out-performance cent drive estim increas
medic suppli devic
pt deriv rang
dcf valuat deriv
base case upsid scenario
supplement ev/fcf ev/
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm ep includ stock compens expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
lower net interest expens higher incom contract
manufactur busi lower tax rate off-set less favor fx
impact year
rate share outperform price target ten consecut
beat rais ep quarter sinc spin oper margin alreadi track ahead
manag current long-rang plan increasingli strong free cash flow gener
believ post-spin new turnaround stori still room signific upsid
believ increment margin upsid potenti alreadi price believ magnitud
sale growth reacceler potenti free cash flow gener still underappreci
level increasingli becom strong free cash flow gener stori free
cash flow target vs potenti upsid free
cash flow view increas financi flexibl invest busi
drive even faster sale growth acceler invest inorgan outsid opportun
supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin
target believ margin expans stori alreadi least partli price
stock manag current guid oper margin
see room upsid margin ramp believ major
upsid alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement ev/
ev/ebitda analys ev/ebitda perspect valuat right line
group includ ew
estim
failur execut margin expans initi new product launch delay possibl
acquisit either dilut perceiv further baxter growth goal could
pressur stock
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu leerink partner estim
baxter sale y/i
sale billion usd
constant currenc basi
revenu report
revenu report
revenu report
constant currenc basi flat
revenu report
revenu report impli
constant currenc
flat sale growth report basi
constant currenc basi
basi constant currenc
sale growth report
currenc basi
report constant
margin expans
bp
oper cf
ex
oper
constant
currenc basi
constant
cyclo clari
constant
currenc basi
constant currenc
basi includ
recothrom
constant
currenc basi
report impli
mid-point
constant currenc basi
margin expans
bp
oper cf
ex
oper
basi
constant
currenc basi
basi
constant currenc
constant
basi
currenc basi
report impli
mid-point
constant currenc basi
margin expans
bp
oper cf
ex
constant currenc
constant
report impli
constant currenc basi
report impli
oper cf
ex
constant currenc basi
report
constant currenc basi
adjust impact
cyclophosphamid competit
impact product exit
constant currenc basi
adjust impact
cyclophosphamid competit
impact product exit
compani report leerink partner estim
oper cf
ex
oper cf
ex
oper cf
ex
ex fx oper
ex fx oper
mid-singl digit
point-of-car solut pd
innov home periton dialysi pd solut system
improv patient access home dialysi new system
design produc steril pd solut use small water filtrat
devic would place patient home integr
sharesourc telehealth platform
theranova technolog design close mimic natur
kidney clearanc certain molecul dialysi get
better level clearanc certain molecul
hdx therapi enabl
hdx therapi extend rang molecul filter
blood dialysi result filtrat profil
close mimic natur kidney addit clearanc profil
hdx enabl theranova simpl perform
convent hemodialysi hd design work
hd machin allow clinic offer hdx therapi use exist
resourc elimin need special equip ad
clinic workflow requir hdf addit hdf
perform effect patient hdx therapi enabl
theranova crucial step bring benefit theranova
patient market
file registr
end
final regulatori pathway fda on-
demand periton dialysi pd system drug-devic combo
expect start clinic trial
oct note market share leader
pd global even introduct poc pd
like grow market rate
januari expect launch
octob begun enrol patient us
first set use continu renal replac therapi
crrt sepsi manag protocol label expans
oxiri blood purif set add baxter multi-organ
therapi offer util prismaflex system
latest technolog acut care therapi
oxiri label expans take effect
countri europ well geographi
east africa began launch label expans
select market outsid
roll-out on-go
februari began limit launch
anticip full european launch later year
expect new product pipelin acceler growth
contribut busi
compani report leerink partner estim
new dialyz could chang game long-term term
hd expect provid uniqu advantag
expect improv outcom convent
hemodialysi use particular dialyz get
better level clearanc certain molecul
amia integr sharesourc technolog allow
patient clinician commun back forth daili
may convert roughli patient
 expect acceler
also sharesourc technolog
compani report leerink partner estim
